Raymond James Thinks Haemonetics Growth Is 'Underappreciated'
Benzinga · 13h ago
Morgan Stanley Maintains Equal-Weight Rating for Haemonetics: Here's What You Need To Know
Morgan Stanley has decided to maintain its Equal-Weight rating of Haemonetics (NYSE:HAE) and raise its price target from $60.00 to $70.00. Shares of Haemonetics are trading up 1.46% over the last 24 hours, at $66.13 per share. A move to $70.00 would accoun...
Benzinga · 13h ago
4 Analysts Have This to Say About Haemonetics
Over the past 3 months, 4 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the ...
Benzinga · 14h ago
Raymond James Adjusts Haemonetics' Price Target to $76 from $63, Keeps Outperform Rating
MT Newswires · 17h ago
Haemonetics Completes Move to New Manufacturing Facility in Clinton, PA
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has fully commenced operations at its new manufacturing Center of Excellen...
PR Newswire · 06/24 10:45
Haemonetics Starts Operations at New Pennsylvania Plant
MT Newswires · 06/24 07:14
Needham Sees Reasonable Forecasts For Haemonetics, With Some Tailwinds
Haemonetics Corporation's (NYSE: HAE) analyst day later this month may include an update on its businesses, new products, margin outlook, and financial targets for FY24-FY26.
Benzinga · 06/15 18:52
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/09 15:30
Haemonetics Corporation Announces Additional Information Regarding Its Investor Day on June 29, 2022
Haemonetics Corporation (NYSE: HAE) has posted its full lineup of speakers planned for the Company's Investor Day, to be hosted in Boston on Wednesday, June 29, 2022, with presentations beginning at 10:00 AM EDT. Information about scheduled speakers and th...
PR Newswire · 06/06 10:00
Haemonetics (HAE) Gains on Procedure Recovery Amid Cost Woes
A strong procedure recovery in the hospital business, the resilience of blood donors in blood centers, and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
Zacks · 05/27 13:59
Insider Sell: Haemonetics
MT Newswires · 05/23 17:44
Here's Why Investors Should Retain Haemonetics (HAE) For Now
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Zacks · 05/23 15:45
Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up
Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Zacks · 05/11 15:12
--Raymond James Lowers Haemonetics Price Target to $63 From $66, Maintains Outperform Rating
MT Newswires · 05/11 12:18
--Barrington Raises Haemonetics Price Target to $77 From $71, Maintains Outperform Rating
MT Newswires · 05/11 11:09
77 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 05/10 16:01
Biohaven, AdaptHealth top healthcare gainers; Bausch Health, GoodRx lead losers' pack
Gainers: Biohaven Pharmaceutical (BHVN) +71%. AdaptHealth (AHCO) +31%. Evaxion Biotech (EVAX) +25%. Assertio (ASRT) +22%. Haemonetics (HAE) +16%. Losers: Bausch Health (BHC) -26%. GoodRx (GDRX) -24%. Akanda (AKAN) -21%. Novavax (NVAX) -12%. Blue Water Vacc...
Seekingalpha · 05/10 14:02
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 11:35
Haemonetics: Q4 Earnings Insights
  Haemonetics (NYSE:HAE) reported its Q4 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 11:26
BRIEF-Haemonetics Corp - QTRLY Revenue $265 Million, Up 18% · 05/10 11:16
Webull provides a variety of real-time HAE stock news. You can receive the latest news about Haemonetics Corp Mass through multiple platforms. This information may help you make smarter investment decisions.
About HAE
Haemonetics Corporation is a healthcare company. The Company provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. It markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.